Article Sidebar
Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
Results of laser treatment for sub-retinal neovascular membranes
Abstract
A retrospective study was carried out to determine the results of laser treatment for choroidal neovascular membranes in age-related macular degeneration in 92 patients in whom fluorescein angiography was performed for this condition over a 7-year period. Twenty-nine of these patients, treated with the argon laser, were followed up regularly for 15 months. The treatment comprised overlapping laser spots of 200 J.Lm and an average power of 390 mW. The results of this study demonstrated that: (i) the majority of membranes were closer ·than 500 J.Lm from the foveola; (ii) the second eye involvement rate in the same patient was 15,79% over 15 months; and (iii) a 37,5% significant visual' loss or 41% two lines or greater visual loss was seen after 15 months, which compares favourably with results of laser treatment reported by other institutions.
